Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Guideline on Preventing VTE in Pediatric Cancer

J Thromb Haemost; ePub 2017 Nov 27; Tullius, et al

The International Society on Thrombosis and Hemostasis has released guidance on identifying at-risk patients and preventing venous thromboembolism in pediatric cancer. Among the recommendations:

  • Perform comprehensive risk assessment on each pediatric cancer patient at the initiation of cancer therapy.
  • Do not administer routine primary thromboprophylaxis in pediatric cancer patients without a history of prior thrombosis.
  • Administer thromboprophylaxis in pediatric cancer patients with prior thrombosis who are continuing to receive intensive therapy, as long as there are no anticoagulation contraindications.
  • Consider thromboprophylaxis on a case-by-case basis for pediatric cancer patients with no history of VTE, but with significant combinations of risk factors, including central venous catheters, asparaginase therapy, obesity, adolescence, hormonal contraceptives, or hospitalization for surgery.

Citation:

Tullius B, Athale U, van Ommen C, Chan A, Palumbo J, Balagtas J. The identification of at-risk patients and prevention of venous thromboembolism in pediatric cancer: Guidance from the SSC of the ISTH. [Published online ahead of print November 27, 2017]. J Thromb Haemost. doi:10.1111/jth.13895.

This Week's Must Reads

Cardiac assessment before doxorubicin treatment , Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85

Ibrutinib dosing changes and the impact on survival, Williams AM et al. Clin Lymphoma Myeloma Leuk. 2018 Oct 12. doi: 10.1016/j.clml.2018.10.005

Adding mobile apheresis to community blood drives, Anthony D et al. AABB 2018, Poster BBC 135

Study assesses blood delivery errors, Vossoughi S et al. AABB 2018, Abstract QT4

CAR T-cell cost effectiveness in ALL, Whittington MD et al. JAMA Pediatr. 2018 Oct 8. doi: 10.1001/jamapediatrics.2018.2530

Must Reads in Bleeding Disorders

Laced synthetic cannabinoid leads to bleeding, Kelkar AH et al. N Engl J Med. 2018;379:1216-23.

Phase 3 data on emicizumab, Mahlangu et al. N Engl J Med. 2018;379:811-22

Integrated programs ease sickle cell pain, hospitalizations, Annual meeting of the Foundation for Sickle Cell Disease Research

Watch for RBC adhesion in men with sickle cell , Annual meeting of the Foundation for Sickle Cell Disease Research

FDA approves Jivi for hemophilia A, Package insert, news release